Skip to main content


30.04.2019 Client news

National prescription drug take back day helps fight drug abuse.

+5,400 tons. That’s how much the DEA has collected of expired, unwanted or unused prescription medications over the past nine years through the National Prescription Drug Take Back Day program.

Last Saturday, nearly 5,000 law enforcement agencies joined forces at approximately 6,000 collection sites across the nation for the April 27th National Prescription Drug Take Back Day.

“Our efforts to reverse the pattern of addiction in America start with preventing drug misuse before it’s too late,” said White House Office of National Drug Control Policy Director James Carroll in a press statement. “In homes across the country, medicine cabinets are full of leftover prescription drugs that have the potential to take someone’s life.”

Approximately 6 million Americans misused controlled prescription drugs — and the majority of those were obtained from family and friends, often from the home medicine cabinet — according to the 2017 National Survey on Drug Use and Health.1

Take Back Day aims to eliminate this threat by offering safe disposal of unused prescription medications to help prevent misuse and potential overdose.

Now in its ninth year, the DEA has collected nearly 11 million pounds — more than 5,400 tons — of unused prescription medications through its Take Back Day events.

Find out more at To learn how MedImpact helps make prescription drugs safer, accessible go to




Read on.
Keep up to date on the latest in the industry.
Client news
FDA approves first and only treatment for common mutation in advanced breast cancer.
The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.
Client news
Can you put a price on life?
FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.
Client news
Investigating top diabetes trends by lines of business.
Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.

Ready for clarity from your PBM?